| Epidemiology of osteoarthritis: literature update |
94 |
| Epidemiology of systemic lupus erythematosus: an update |
29 |
| Rheumatoid arthritis and citrullination |
28 |
| Epidemiology of axial spondyloarthritis: an update |
22 |
| Inflammation in bone physiology and pathology |
19 |
| Cardiovascular disease in systemic lupus erythematosus: an update |
18 |
| Exercise in the management of knee and hip osteoarthritis |
18 |
| Targeting aging for disease modification in osteoarthritis |
17 |
| Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update |
16 |
| What are the dominant cytokines in early rheumatoid arthritis? |
15 |
| Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions |
13 |
| Management of systemic sclerosis-associated interstitial lung disease |
12 |
| Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification? |
12 |
| The compleaes of fibromyalgia and its comorbidities |
11 |
| Extra-pulmonary diseases related to Mycoplasma pneumoniae in children: recent insights into the pathogenesis |
11 |
| Complement, infection, and autoimmunity |
11 |
| The microbiome in systemic autoimmune disease: mechanistic insights from recent studies |
11 |
| An update on the role of type I interferons in systemic lupus erythematosus and Sjogren's syndrome |
10 |
| Drug-induced lupus erythematosus: an update on drugs and mechanisms |
10 |
| Extracellular vesicles in cartilage homeostasis and osteoarthritis |
10 |
| Arthritis risk with immune checkpoint inhibitor therapy for cancer |
9 |
| Calcinosis in scleroderma |
9 |
| Artificial intelligence, osteoporosis and fragility fractures |
9 |
| Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes |
9 |
| The diagnostic work-up of cancer-associated myositis |
8 |
| Current views on the pathogenesis of Sjogren's syndrome |
8 |
| Glucocorticoid-induced osteoporosis update |
8 |
| Development and use of biochemical markers in osteoarthritis: current update |
8 |
| Pathogenesis and treatment of autoimmune rheumatic diseases |
7 |
| Neutrophil extracellular traps in vasculitis, friend or foe? |
7 |
| Update on the genetics of nonbacterial osteomyelitis in humans |
7 |
| New insights in myositis-specific autoantibodies |
7 |
| Epigenetics of inflammatory arthritis |
7 |
| New insights into IgG4-related disease: emerging new CD4(+) T-cell subsets |
7 |
| Sex bias in autoimmunity |
7 |
| Using technology to support clinical care and research in rheumatoid arthritis |
7 |
| Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus |
6 |
| Recent advances in the treatment of rheumatoid arthritis |
6 |
| Mortality and survival in systemic sclerosis: a review of recent literature |
6 |
| Microbiome and autoimmune diseases: cause and effect relationship |
6 |
| The role of Epstein-Barr virus infection in primary Sjogren's syndrome |
6 |
| Antisynthetase syndrome pathogenesis: knowledge and uncertainties |
6 |
| Porphyromonas gingivalis and rheumatoid arthritis |
6 |
| Uric acid and cognitive decline: a double-edge sword? |
6 |
| The use of biologics for uveitis associated with spondyloarthritis |
6 |
| Application of machine learning in the diagnosis of axial spondyloarthritis |
6 |
| The evolving role of anabolic therapy in the treatment of osteoporosis |
6 |
| The utility and limitations of using trabecular bone score with FRAX |
6 |
| Management of scleroderma renal crisis |
6 |
| Treatment of neuromyelitis optica spectrum disorders |
6 |
